Company overview
Phylloceuticals develops plant-based bioprocessing technology (PhAAST™) using genetically modified tobacco (Nicotiana sp.) and Lemna sp. to produce therapeutic proteins, vaccine antigens, and antibodies faster and cheaper than traditional mammalian cell methods. The automated hydroponic and aquaculture systems enable rapid scaling, such as 50 million vaccine doses in 12 weeks, with no animal-derived products or human contact required. They focus on biosimilars, novel drugs, animal health, and clinical trial materials as a supplier to commercialization entities.
Phylloceuticals is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents partner serving United States & Americas. Core focus areas include plant-based biologics, therapeutic proteins, vaccine antigens, biosimilars, phaast technology.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.phylloceuticals.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- plant-based biologics, therapeutic proteins, vaccine antigens, biosimilars, phaast technology
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What bioprocessing technology does Phylloceuticals use?
- Phylloceuticals employs PhAAST™, an automated plant-based platform using hydroponically grown Nicotiana sp. and aquaculture-grown Lemna sp. to produce properly folded therapeutic proteins, vaccine antigens, and antibodies matching or exceeding human glycoforms.
- What products can Phylloceuticals manufacture?
- They produce biosimilars, novel drugs, animal health therapeutics, and clinical trial investigation materials, including kilograms of product in weeks via plant expression systems.
- What are the advantages of Phylloceuticals' plant-based approach?
- The technology offers faster production (e.g., 50 million vaccine doses in 12 weeks), lower costs (facilities under $120M vs. $1B+), reduced risk with no animal products or human contact, and no need for viral clearance studies.
Related editorial coverage
- FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
- Biosimilars Drive Significant Reductions in Specialty Drug Spending
- FDA's Bayesian Methodology: A Game Changer for Drug Development
- Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates
- Biosimilars Market Analysis: US Landscape Post-Inflation Reduction Act 2026
- Biosimilars Market Analysis: Impact of Recent FDA Approvals on US Pricing & Competition
Explore lab tools and QA/QC resources for R&D teams.
